Hong Kong Stock Alert | GIANT BIOGENE (02367) Falls Over 5% Ahead of Interim Results Disclosure, Previous Negative Coverage Impacted 618 Promotional Performance

Stock News

Aug 27

GIANT BIOGENE (02367) declined over 5%. As of press time, the stock was down 5.7% to HK$54.6, with turnover reaching HK$560 million.

On the news front, GIANT BIOGENE will hold a board meeting today to approve its interim results for 2025. China Merchants Securities International previously noted that negative media coverage dragged down the company's 618 shopping festival performance, with GMV growth slowing to mid-single-digit percentages year-over-year in May and June. The firm expects the company to achieve revenue and net profit of RMB 3.1 billion and RMB 1.2 billion respectively in the first half of 2025, mainly benefiting from Comfy and Collgene recording sales growth of approximately 25% and over 50% respectively. The target price remains unchanged at HK$77.0.

Caitong Securities believes that Kemei's data showed month-over-month improvement after resuming live streaming in July, and expects sales to gradually recover in the second half of the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1144368094"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144368094\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144368094?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-27 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144368094","market":"other","top_or_hot":-1,"title":"Hong Kong Stock Alert | GIANT BIOGENE (02367) Falls Over 5% Ahead of Interim Results Disclosure, Previous Negative Coverage Impacted 618 Promotional Performance","media":"Stock News","content":"<p>GIANT BIOGENE (02367) declined over 5%. As of press time, the stock was down 5.7% to HK$54.6, with turnover reaching HK$560 million.</p>\n<p>On the news front, GIANT BIOGENE will hold a board meeting today to approve its interim results for 2025. China Merchants Securities International previously noted that negative media coverage dragged down the company's 618 shopping festival performance, with GMV growth slowing to mid-single-digit percentages year-over-year in May and June. The firm expects the company to achieve revenue and net profit of RMB 3.1 billion and RMB 1.2 billion respectively in the first half of 2025, mainly benefiting from Comfy and Collgene recording sales growth of approximately 25% and over 50% respectively. The target price remains unchanged at HK$77.0.</p>\n<p>Caitong Securities believes that Kemei's data showed month-over-month improvement after resuming live streaming in July, and expects sales to gradually recover in the second half of the year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | GIANT BIOGENE (02367) Falls Over 5% Ahead of Interim Results Disclosure, Previous Negative Coverage Impacted 618 Promotional Performance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | GIANT BIOGENE (02367) Falls Over 5% Ahead of Interim Results Disclosure, Previous Negative Coverage Impacted 618 Promotional Performance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-27 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GIANT BIOGENE (02367) declined over 5%. As of press time, the stock was down 5.7% to HK$54.6, with turnover reaching HK$560 million.</p>\n<p>On the news front, GIANT BIOGENE will hold a board meeting today to approve its interim results for 2025. China Merchants Securities International previously noted that negative media coverage dragged down the company's 618 shopping festival performance, with GMV growth slowing to mid-single-digit percentages year-over-year in May and June. The firm expects the company to achieve revenue and net profit of RMB 3.1 billion and RMB 1.2 billion respectively in the first half of 2025, mainly benefiting from Comfy and Collgene recording sales growth of approximately 25% and over 50% respectively. The target price remains unchanged at HK$77.0.</p>\n<p>Caitong Securities believes that Kemei's data showed month-over-month improvement after resuming live streaming in July, and expects sales to gradually recover in the second half of the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1144368094","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144368094","pubTimestamp":1756274421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GIANT BIOGENE (02367) declined over 5%. As of press time, the stock was down 5.7% to HK$54.6, with turnover reaching HK$560 million. On the news front, GIANT BIOGENE will hold a board meeting today...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK1207":"个人用品"},"translate_title":"港股快讯|巨人生物基因(02367)中期业绩披露前跌超5%前期利空覆盖冲击618促销表现","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"GIANT BIOGENE (02367) declined over 5%. As of press time, the stock was down 5.7% to HK$54.6, with turnover reaching HK$560 million.\nOn the news front, GIANT BIOGENE will hold a board meeting today to approve its interim results for 2025. China Merchants Securities International previously noted that negative media coverage dragged down the company's 618 shopping festival performance, with GMV growth slowing to mid-single-digit percentages year-over-year in May and June. The firm expects the company to achieve revenue and net profit of RMB 3.1 billion and RMB 1.2 billion respectively in the first half of 2025, mainly benefiting from Comfy and Collgene recording sales growth of approximately 25% and over 50% respectively. The target price remains unchanged at HK$77.0.\nCaitong Securities believes that Kemei's data showed month-over-month improvement after resuming live streaming in July, and expects sales to gradually recover in the second half of the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}